CClinicalTrials.gg
RecruitingNCT07003386Updated Sep 16, 2025

Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke

A Phase 2/3 interventional study of Galantamine and Standard treatment for acute ischemic stroke in Acute Ischemic Stroke AIS, sponsored by Shanghai Yueyang Integrated Medicine Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Shanghai Yueyang Integrated Medicine Hospital · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Although mechanical thrombectomy or thrombolytic therapy for large vessels can achieve a revascularization rate (TICI ≥2b) of over 90%, 30-50% of patients still exhibit poor functional outcomes. This phenomenon of "ineffective reperfusion" suggests that microcirculatory dysfunction plays a decisive role in post-stroke neural injury. Therefore, it is necessary to combine brain protection strategies with microcirculatory reperfusion therapy to improve the functional prognosis of stroke patients.Increasing cerebral blood flow (CBF) and neurovascular unit (NVU)-based cerebral protection are current hotspots in the emergency treatment of stroke.

Galantamine, extracted from Lycoris aurea (a traditional Chinese medicinal herb), is an acetylcholinesterase inhibitor (AChEI) that has been widely recognized for improving cerebral blood flow and modulating inflammatory responses in ischemic stroke (IS).

Therefore, the applicant will conduct an internationally compliant, randomized controlled clinical study with routine treatment to evaluate the efficacy of galantamine in the treatment of acute cerebral infarction. This project will conduct a comprehensive assessment of the drug's efficacy from multiple aspects, including improvements in stroke-related outcomes, Traditional Chinese Medicine (TCM) syndrome manifestations, cognitive function, cerebral blood flow, and inflammatory factors.

02

Conditions studied

  • Acute Ischemic Stroke AIS
03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged > 18 years and \< 85 years, regardless of gender
  • Meeting the diagnostic criteria for ischemic stroke in Western medicine
  • Meeting the diagnostic criteria for stroke (Zhongfeng) in Traditional Chinese Medicine (TCM)
  • Diagnosis of acute ischemic stroke within 72h of symptom onset
  • A score of 4-25 points on the National Institute of Health Stroke Scale (NIHSS)
  • First onset of the disease, or no severe sequelae related to previous onset
  • The patient and their legal guardian voluntarily sign the informed consent form for the study

Exclusion criteria

Exclusion Criteria:

  • Confirmed by cranial imaging examination to have diseases causing similar symptoms such as brain tumors, encephalitis, and brain abscesses; or confirmed to have hemorrhagic cerebral infarction,epidural hematoma,intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.
  • Patients with severe abnormalities of liver and kidney function (liver function: alanine aminotransferase [ALT] >2 times the upper limit of normal [ULN]; renal function: creatinine [Cr]>1.5 times the upper limit of normal [ULN])
  • Elderly patients with physical weakness or patients complicated with infection
  • Patients with a history of mental illness or dementia
  • Patients with other severe organ or systemic diseases, accompanied by malignant tumors in any organ or system, or undergoing anti-tumor treatment, with an expected survival time of \< 6 months
  • A significant history of drug or alcohol abuse
  • Women who test positive for blood human chorionic gonadotropin (HCG) (i.e., HCG ≥ 5 mIU/mL) during pregnancy screening, plan to become pregnant during the trial, or are breastfeeding
  • Patients who are currently participating in other clinical trials or have participated in other clinical trials within the past 1 month
  • Patients who are currently using other cholinesterase inhibitor drugs or have used other cholinesterase inhibitor drugs within the past 3 months
  • Patients with epilepsy, hyperkinesis, mechanical intestinal obstruction, bronchial asthma, angina pectoris, bradycardia, or glaucoma
  • Patients with contraindications to brain magnetic resonance imaging (MRI) examination, such as patients with implanted cardiac pacemakers, patients with implanted artificial joints or orthopedic plates, patients with claustrophobia, etc
04

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    galantamine group

    Standard treatment for acute ischemic stroke and galantamine

    Drug: Galantamine · Drug: Standard treatment for acute ischemic stroke

  • Sham comparator
    Control group

    Standard treatment for acute ischemic stroke

    Drug: Standard treatment for acute ischemic stroke

Interventions

  • DrugGalantamine

    Start within 24 hours of hospitalization, administer 5.0 mg of galantamine via intramuscular injection once daily, and continue the treatment for 10 days.

    Also known as: Galantamine from Lycoris aurea extract

  • DrugStandard treatment for acute ischemic stroke

    Standard treatment for acute ischemic stroke

    Also known as: Routine Western medical treatment according to guidelines

05

What researchers measure

Primary outcomes

  1. The change in NIHSS score

    Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits

    Time frame: Randomization Day,Day 10 (±2 days),Day 30 (±4 days) and Day 90 (±7 days)

Secondary outcomes

  1. Scores assessed by Fugl-Meyer motor assessment (FMA)

    Scores on the Fugl-Meyer motor assessment (FMA) range from 0 to 100,with lower scores indicating more severe the motor dysfunction

    Time frame: Randomization Day,Day 10 (±2 days),Day 30 (±4 days) and Day 90 (±7 days)

  2. Cerebral Blood Flow

    The cerebral blood flow is evaluated by MRI

    Time frame: Randomization Day,Day 30 (±4 days)

  3. Fractional anisotropy (FA) values

    The fractional anisotropy (FA) values is evaluated by MRI

    Time frame: Randomization Day,Day 30 (±4 days)

  4. TNF-α

    Laboratory parameters obtained through venous blood analysis

    Time frame: Randomization Day,Day 10 (±2 days)

  5. IL-6

    Laboratory parameters obtained through venous blood analysis

    Time frame: Randomization Day,Day 10 (±2 days)

  6. Modified Rankin Scale (mRS) score

    The mRs is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death)

    Time frame: Randomization Day,Day 10 (±2 days),Day 30 (±4 days) and Day 90 (±7 days)

  7. Scores assessed by Mini-Mental State Examination (MMSE)

    The MMSE is a brief 30-point questionnaire test that is used to screen for cognitive impairment. A score greater than or equal to 25 points is effectively normal (intact). Below this, scores can indicate severe (≤9 points), moderate (10-20 points) or mild (21-24 points) cognitive impairment

    Time frame: Randomization Day,Day 10 (±2 days),Day 30 (±4 days) and Day 90 (±7 days)

  8. Scores assessed by Montreal Cognitive Assessment (MoCA)

    MoCA scores range between 0 and 30. Higher scores indicate a better outcome, and a score of 26 or over is considered to be normal

    Time frame: Randomization Day,Day 10 (±2 days),Day 30 (±4 days) and Day 90 (±7 days)

  9. Traditional Chinese Medicine (TCM) syndrome manifestations

    Under the guidance of Traditional Chinese Medicine (TCM) theory, evaluate the drug's effect on improving TCM syndrome manifestations (such as hemiplegia, deviated mouth and tongue, and speech impairment).

    Time frame: Randomization Day,Day 10 (±2 days),Day 30 (±4 days) and Day 90 (±7 days)

  10. Barthel Index Score

    It is used to measure the ability of patients (especially those with stroke, geriatric diseases, or in the rehabilitation period) to independently complete daily activities such as eating, dressing, walking, and using the toilet. The scoring range is 0-100 points, with higher scores indicating stronger self-care ability in daily life.

    Time frame: Randomization Day,Day 10 (±2 days),Day 30 (±4 days) and Day 90 (±7 days)

  11. EQ-5D Scale Score

    It is an internationally accepted assessment tool for "Health-Related Quality of Life (HRQoL)". Its core function is to quantitatively evaluate an individual's health status and quality of life through five dimensions: "mobility, self-care, usual activities, pain/discomfort, and anxiety/depression". It is widely used in clinical trials, health economics research, and chronic disease management (e.g., comprehensive evaluation of treatment effects in stroke patients).

    Time frame: Randomization Day,Day 10 (±2 days),Day 30 (±4 days) and Day 90 (±7 days)

06

Study locations

1 of 1 sites recruiting
  • Shanghai Yueyang Integrated Medicine Hospital
    Shanghai, Shanghai Municipality 200080, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07003386
Lead sponsor
Shanghai Yueyang Integrated Medicine Hospital
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Sep 14, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Sep 16, 2025

Study contacts

Chunxiang Chen
Contact
768449109@qq.com
+8618616537797
Chunxiang Chen
study chair · Shanghai Yueyang Integrated Medicine Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion